The highest risk of any infection was in those with myelofibrosis (HR 3·7) compared to those with PV or ET (HR 1·7), and there was no difference in infection rates in patients with ET or PV who were not receiving treatment compared to those who were receiving hydroxyurea, IFN or anagrelide.39 This evidence concerns the gene IFNA1 and acquired polycythemia vera.